Title
Quality of life: 1. Perspectives
Author
Banta, H.D.
Nederlands Instituut voor Praeventieve Gezondheidszorg TNO
Publication year
1993
Abstract
Assessing the value of health care interventions is more and more a concern of governments, clinicians, health insurance companies, policy makers, and the general public. One dimension of the outcomes of such interventions that has received relatively little attention until recently is quality of life. However, during the last decade, measuring quality of life has become more frequent. Methodologies have also developed rapidly. At the same time, methodological problems continue to be troubling. In part, this explains the relative lack of use of validated measures of quality of life in clinical trials. In the future, measuring quality of life will certainly become more frequent. It may even be demanded by policy making bodies. Increasingly, too, economic costs will be part of such studies. This requires considering both clinical and economic data. Chemicals/CAS: erythropoietin, 11096-26-7
Subject
Health
Drug therapy
Erythropoietin
Methods
Clinical trial
Economics
Health care
Human
Major clinical study
Methodology
Review
Cost-Benefit Analysis
Human
Quality of Life
To reference this document use:
http://resolver.tudelft.nl/uuid:3446977d-3d23-490f-b98c-032c225bc051
TNO identifier
232045
ISSN
0928-1231
Source
Pharmacy World and Science, 15 (2), 45-49
Document type
article